Peptide R54

Peptide R54 (Pep R54; CXCR4 antagonist peptide 19) is an antagonistic peptide targeting CXCR4 with significant anticancer activity. Peptide R54 inhibits CXCR4-dependent cell migration, epithelial-mesenchymal transition, and lung metastasis development, with better serum stability and higher CXCR4 affinity than the lead compound (IC50=20 nM) . Peptide R54 synergizes with anti-PD-1 therapy to exert anti-tumor activity in vivo, enhances granzyme activity, and reduces infiltration of Foxp3 cells. Peptide R54 can be used in the study of colon cancer, ovarian cancer, and melanoma[1][2].

Pep R54; CXCR4 antagonist peptide 19

12352209

CXCR

GPCR/G Protein; Immunology/Inflammation

Cancer

O=C(N[C@@H](C)C(CN[C@H](CSSC(C)(C)[C@@H](C(O)=O)NCC([C@H](CC1=CNC=N1)NCC2=O)=O)C(N[C@@H](CCCNC(N)=N)C(CN[C@@H]2CC3=CC=C4C=CC=CC4=C3)=O)=O)=O)[C@H](CCCNC(N)=N)NC(C)=O

C48H71N15O9S2

1066.30

[1]D'Alterio C, et al. Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1. J Exp Clin Cancer Res. 2019 Oct 28;38 (1) :432.|[2]Russo D, et al. The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human ovarian cancer cells. PLoS One. 2024 Dec 19;19 (12) :e0314735.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P11011/

Peptides

No Development Reported

CXCR4